You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflows
SBC: 490 BIOTECH INC Topic: 300Development of a high throughput screen to detect the effects of both preand postbiotransformed compounds for enhanced content drug discovery workflows Project Summary This Small Business Innovation Research Phase II project will build upon our successful Phase I demonstration that substrate free autobioluminescent signal generation can detect both the preand post biotransformed metabolic impacts ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel Inhibitors of PSMB and PSMB for the Treatment of Multiple Myeloma
SBC: InhiProt Topic: 103Multiple myeloma is incurable hematologic malignancy with an expected median survival of years The proteasome inhibitors bortezomib carfilzomib and the recently approved ixazomib are a mainstay of current myeloma treatment Despite an initial response rate approaching to proteasome inhibitor containing combinations all patients relapse and eventually become resistant to any treatments ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of PEGylated MTI for the treatment of relapsed Myeloma
SBC: MODULATION THERAPEUTICS, INC. Topic: 102ABSTRACT Modulation Therapeutics is developing a first in class cyclic peptide coined MTI for the treatment of multiple myeloma The company currently has a license for the parent molecule which has been awarded a patent covering the intellectual property for both composition of matter and use in cancer in the US and Europe Modulation Therapeutics is now poised to further advance this class ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents
SBC: BIOVENTURES, INC Topic: 172Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Shear Thickening Fluid Enhanced Textiles for Durable, Puncture- and Cut-Resistant Environmental Protection Garments
SBC: STF TECHNOLOGIES LLC Topic: T601This Small Business Technology Transfer Research Phase II will develop and advance the commercialization of STF-ArmorTM nanocomposite materials for use in Environmental Protection Garments (EPG) for extended exploration missions in diverse environments, including LEO, cis-lunar space, and Lunar and Martian surfaces. The Phase II research will optimize and deliver a validated prototype suit compon ...
STTR Phase II 2017 National Aeronautics and Space Administration -
Robust Predictor of Breast Cancer Risk
SBC: Morgan and Mendel Genomics, Inc. Topic: 103Summary Approximatelymillion women in the United States are at high risk for developing breast cancerbased on inheritance of a germline mutation in a gene in the double strand breakDSBrepair and cyclin checkpoint pathwaysMany are unaware of their genetic predispositionsbecause their family history is uninformative or unknownGenetic testing is important for identifying mutations in these genesbut i ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A single-cell device to capture and analyze rare T-cells from solid tumors.
SBC: ISOPLEXIS CORPORATION Topic: 102Checkpoint inhibitors towards targets such as PDand PD Lare being developed to activate quiescent T cells embedded in tumors and enable them to recruit the rest of the immune system to fight a cancer massHow these new cures reactivate the relatively few Tumor Infiltrating LymphocytesTILsenabling the release of a complex message of cytokines to recruit the immune systemthus impacting treatment effi ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Active Radiation Shield
SBC: GLOYER-TAYLOR LABORATORIES INC Topic: T301In the Phase I effort, Gloyer-Taylor Laboratories LLC (GTL) verified the feasibility of generating power from space particle radiation. This effort successfully demonstrated electrical power production from a particle radiation source using an initial proof-of-concept device. The effort also identified a second approach that has the potential for even better power generation and offers enhanced ...
STTR Phase II 2017 National Aeronautics and Space Administration -
A single-cell mouse proteomic system to accelerate pre-clinical immune therapeutics
SBC: ISOPLEXIS CORPORATION Topic: 100With this PhasesubmissionIsoPlexis proposes to deliver a single cell proteomic solution for ultra sensitive detection of unique correlative biomarkers in pre clinical mouse modelsin an automated system that can be used to accelerate the discovery of potential immune therapeuticsThe recent revolution in new basic science discovery is failing to translate into improved patient treatmentThe reduction ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Cellular Immunotherapy for SSc
SBC: CELDARA MEDICAL, LLC Topic: NIAMSProject Summary Systemic sclerosis SSc is a systemic autoimmune disease that results in widespread fibrosis of the skin and internal organs vascular dropout and autoantibody formation SSc has the highest case fatality rate of any systemic autoimmune disease and there remain for FDA approved therapies Analysis of gene expression data on samples collected from SSc patients strongly indicates th ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health